HIGHLIGHTS
- who: Joana Dias Apolu00f3nio from the Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve have published the research work: THOR is a targetable epigenetic biomarker with clinical implications in breast cancer, in the Journal: (JOURNAL)
- what: The authors aimed to investigate the role of as and explore the functional impact of status in hTERT upregulation in BC. The authors show that THOR hypermethylation can serve as a robust and simple tool for BC screening and early diagnosis. The authors focused the analysis on the THOR region within the hTERT promoter, for which open . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.